Restricting Fluoroquinolone Use Helped With CDI Decline in England

Share this content:
<i>C difficile</i> outbreak that began in England in 2006 was curbed by reducing the use of fluoroquinolones. <i>Photo Credit: CDC/James Archer.</i>
C difficile outbreak that began in England in 2006 was curbed by reducing the use of fluoroquinolones. Photo Credit: CDC/James Archer.

HealthDay News — Reducing the use of fluoroquinolones has curbed an outbreak of Clostridium difficile that began in 2006 in England, according to a study published The Lancet Infectious Diseases.

"Emergency measures -- such as 'deep cleaning' and careful antibiotic prescribing -- were introduced [after the outbreak began] and numbers of C difficile infections gradually fell by 80%, but no one was sure precisely why," study coauthor Derrick Crook, MBBCh, a professor of microbiology at the University of Oxford in the United Kingdom, said in a university news release.

The researchers analyzed hospital data related to the outbreak and found that, among the outbreak, the smaller number of cases of diarrhea caused by C difficile infections that were not resistant to fluoroquinolone antibiotics stayed the same.

"Our study shows that the C difficile epidemic was an unintended consequence of intensive use of an antibiotic class, fluoroquinolones, and control was achieved by specifically reducing use of this antibiotic class, because only the C difficile bugs that were resistant to fluoroquinolones went away," Crook explained. "Reducing the type of antibiotics like ciprofloxacin was, therefore, the best way of stopping this national epidemic of C difficile, and routine, expensive deep cleaning was unnecessary."

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.


Dingle KE, Didelot X, Quan TP, et al; Modernising Medical Microbiology Informatics Group. Effects of control interventions on Clostridium difficile infection in England: an observational study [published online January 24, 2017]. Lancet Infect Dis. doi: 10.1016/S1473-3099(16)30514-X

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters